Wilmington Biologics Center of Excellence
Merck & Co., Inc., Wilmington, New Castle County, Delaware
Wilmington Biologics Center of Excellence in Wilmington, Delaware is Merck & Co., Inc.’s plant for biologics including KEYTRUDA (pembrolizumab) and antibody-drug conjugates. Status: under construction as of April 29, 2025 (groundbreaking). Merck & Co., Inc. announced $1.0 billion and 500 jobs. Primary source: merck.com, checked November 12, 2026.
- Status
- Under construction
- Announced investment
- $1.0 billion
- Announced jobs
- 500
- Industry
- Pharmaceuticals
- Sheet
- DE-02
- Revised
- November 12, 2026
Status timeline
- Groundbreakingmerck.com
Filled dots are confirmed by a company, state, SEC or federal source. Dashed dots come from news reports only. Investment and job figures are as announced, not achieved.
Plant facts
| Company | Merck & Co., Inc. |
|---|---|
| Plant | Wilmington Biologics Center of Excellence |
| Location | Wilmington, New Castle County, Delaware |
| Industry | Pharmaceuticals |
| Product | Biologics including KEYTRUDA (pembrolizumab) and antibody-drug conjugates |
| Announced investment | $1.0 billion470,000 sq ft at Chestnut Run Innovation & Science Park |
| Announced jobs | 500 |
| Last checked | November 12, 2026 |
Sources
- Merck breaks ground on $1 billion Biologics Center of Excellence in Wilmington, Delaware (company release, merck.com, checked November 12, 2026)
Something changed? Send a correction with a link and we'll recheck it.